🚨Scoop from @hannahkuchler & me🚨JPM dealmaking is underway. GSK is nearing a $1bn deal for IDRx, an Andreessen and RA-backed biotech developing a targeted therapy for a rare gastrointestinal cancer https://t.co/pO9R834WcU https://t.co/GR1vK68Bzf
GSK NEARS $1BN DEAL FOR BIOTECH DEVELOPING DRUG FOR RARE TUMOUR- FT
GSK Nears $1 Bln Deal For Biotech Developing Drug For Rare Tumour $GSK
Orbis Medicines has successfully raised €90 million (approximately $93 million) in a Series A funding round aimed at developing oral macrocycle drugs that target popular biologic therapies. The funding round, which marks the beginning of 2025's fundraising tracker, was led by NEA and included prominent investors such as Novo Holdings and Eli Lilly. The Danish biotech firm plans to utilize automated chemistry and machine learning to enhance its drug design capabilities. This financing is part of a growing trend in Denmark, which is emerging as a significant hub for biotech innovation.
